China Metamizole Sodium USP FOB Shanghai prices continued to remain firm during the first half of July 2026 as Latin American, Middle Eastern, and Eastern European generic pharmaceutical manufacturers sustained baseline procurement. Metamizole Sodium USP retains a strong market position across these regions where it remains widely prescribed for pain and fever management despite restrictions in parts of the European market. The firm pricing trend follows the gains recorded in June, supported by steady export demand and constrained prompt availability.
During June, China Metamizole Sodium USP FOB Shanghai prices rose 1.82% month-on-month as exporters and domestic producers implemented firmer offers amid sustained export demand. Early June witnessed disciplined domestic operating rates alongside expanding offtake from Brazil, Mexico, and Egypt. Mid-month developments, particularly the closure of the National Volume-Based Procurement (NVBP) ordering window on 17 June, encouraged hospital replenishment activities and accelerated call-offs from Latin American formulators. At the same time, worsening Shanghai port congestion, with waiting times extending to 4–5 days, tightened prompt supply and supported stronger FOB booking activity for Metamizole Sodium USP.
Demand for Metamizole Sodium USP remained firmly anchored within pharmaceutical manufacturing and regional formulation sectors. Generic drug manufacturers and OTC/prescription medicine producers maintained healthy procurement volumes for analgesic APIs and Novalgina/generic dipyrone brands. The pharmaceutical manufacturing segment continued to demonstrate resilience as Brazilian formulators, including EMS Pharma, Aché, and Eurofarma, accelerated Q3–Q4 purchasing programs to support upcoming formulation runs. International specialty distributors also contributed additional demand by advancing FOB bookings intended to secure Q1 2027 requirements. Hospitals further supported consumption through NVBP-related inventory replenishment activities.
Supply-side fundamentals also contributed to the firm tone in the Metamizole Sodium USP market. Benzene-derived intermediates and methanol-based formaldehyde moved higher during June, increasing upstream production costs and limiting producers’ pricing flexibility. Environmental compliance measures and routine effluent testing across Jiangsu and Shandong continued to keep effective operating rates below nameplate capacity, supporting firmer offers. However, no significant plant shutdowns were reported, and major producers such as Shandong Xinhua Pharmaceutical and Hebei Jiheng maintained steady utilization levels. Additionally, logistics disruptions and Peak Season Surcharges reduced prompt availability, further strengthening the market for Metamizole Sodium USP.
Looking ahead, Metamizole Sodium USP prices are expected to remain firm through July as procurement from Latin America, the Middle East, and Eastern Europe continues at healthy levels. Seasonal formulation demand, ongoing logistics constraints, and exposure to benzene and methanol-based feedstock markets are likely to support pricing. While modest increases may persist through the peak procurement season, market participants will continue monitoring supply chain conditions and upstream cost developments for future direction in the Metamizole Sodium USP market.
Leave a Comment
Comments (0)